Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
KKR & Francisco Partners Competing in $3bn Bid for Instructure
Private equity firms KKR and Francisco Partners are competing to acquire Instructure, a U.S. education software provider with a market value of $3.4bn. The two buyout firms are through to the final round of bidding for Instructure and are preparing to submit binding...
Bain, Cinven Weighing Joint Bid for $20bn Sanofi Unit
Private equity firms Bain Capital and Cinven are exploring a potential joint bid for French drugmaker Sanofi SA’s $20bn consumer health division, people familiar with the matter said. Advent International is speaking to potential partners including sovereign wealth...
CVC completes Acquisition of DIF and Glendower
CVC has completed the acquisition of DIF Capital Partners and the acquisition of the final 20% stake in Glendower Capital, with the latter having been rebranded with immediate effect as CVC Secondary Partners, and the former as CVC DIF. The respective investment...